Rejuvenate Biomed, a clinical-stage company advancing therapeutics to delay the onset of age-related diseases, has completed a six-week clinical proof-of-mechanism study with lead candidate RJx-01 for the treatment of sarcopenia. Sarcopenia is a musculoskeletal disease characterised by the progressive loss of skeletal muscle strength and mass, which manifests chronically with age or as an […]
